Article Details

FDA Requests Belantamab Mafodotin for R/R Multiple Myeloma Be Pulled From US Market

Retrieved on: 2022-11-22 23:02:40

Tags for this article:

Click the tags to see associated articles and topics

FDA Requests Belantamab Mafodotin for R/R Multiple Myeloma Be Pulled From US Market. View article details on HISWAI: https://www.targetedonc.com/view/fda-requests-belantamab-mafodotin-for-r-r-multiple-myeloma-be-pulled-from-us-market

Excerpt

... treated with at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.

Article found on: www.targetedonc.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up